ENZ - Enzo Biochem, Inc.

NYSE - NYSE Delayed Price. Currency in USD
2.5500
-0.0600 (-2.30%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close2.6100
Open2.5900
Bid2.5300 x 1200
Ask2.5400 x 4000
Day's Range2.5000 - 2.6000
52 Week Range2.4000 - 4.4600
Volume141,159
Avg. Volume79,493
Market Cap121.27M
Beta (5Y Monthly)1.17
PE Ratio (TTM)170.00
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • Business Wire

    All Three Proxy Advisory Firms Recommend Shareholders Vote FOR Change to the Board of Enzo Biochem on the Blue Card

    Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today announced that Egan-Jones Proxy Services ("Egan-Jones") has recommended shareholders vote for both HDF nominees on the Blue proxy card. All three leading proxy advisors – Egan-Jones, Glass, Lewis and Co. ("Glass Lewis") and Institutional Shareholder Services Inc. ("ISS") – have now supported HDF’s case for change at Enzo.

  • Business Wire

    Enzo Biochem Comments on ISS Report

    Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable and fully-automated platforms and related products and services that enable its customers to meet their clinical needs, today commented on the report Institutional Shareholder Services (ISS) issued in connection with the upcoming Annual Shareholder Meeting.

  • Business Wire

    ISS Recommends Shareholders Vote FOR the Election of Harbert Discovery Fund Nominee to Enzo Biochem Board

    Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today announced that a leading proxy advisory firm, Institutional Shareholder Services Inc. ("ISS"), has recommended that shareholders vote on the BLUE proxy card in support of HDF’s nominee, Fabian Blank.

  • Business Wire

    Glass Lewis Recommends Shareholders Vote For the Election of Both Harbert Discovery Fund Nominees to Enzo Biochem’s Board

    Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today announced that a leading proxy advisory firm, Glass, Lewis & Co. ("Glass Lewis"), has recommended that shareholders vote on the BLUE proxy card in support of HDF’s two highly-qualified independent nominees, Fabian Blank and Peter Clemens.

  • Business Wire

    Enzo Biochem Responds to Series of Misleading and Inaccurate Statements from Activist Hedge Fund Harbert

    The Board of Directors of Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable and fully-automated platforms and related products and services that enable its customers to meet their clinical needs, today responded to a series of misleading and inaccurate statements in an investor presentation and press release filed by activist investor Harbert Discovery Fund ("Harbert") regarding the Company’s significant accomplishments. The Board believes that Harbert’s campaign of disinformation is designed to divert attention from its inferior slate of underqualified nominees and weak arguments bereft of any true understanding of Enzo’s business or market. With Harbert steadfastly seeking to change 40% of the Board (which would result in only a single independent director remaining with more than a few weeks of experience on our Board), it is critical that the Company set the record straight so shareholders can make a fully informed decision at the upcoming Annual Shareholder meeting.

  • Business Wire

    Harbert Discovery Fund Releases Detailed Investor Presentation Highlighting Case for Change at Enzo Biochem

    Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owner of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today released a detailed investor presentation on Enzo. The presentation outlines the Company’s history of value destruction, persistent underperformance, and corporate governance issues and details HDF’s Nominees’ strategic plan to realize value at Enzo.

  • Business Wire

    Enzo Biochem Appoints Rebecca J. Fischer to Board of Directors

    Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical needs, today announced it has appointed industry healthcare veteran and leader Rebecca J. Fischer to its Board of Directors. Her appointment as a new independent director is effective immediately and follows a search process conducted as part of Enzo’s ongoing focus on Board composition, refreshment and diversity. As part of our evaluation, the Company as a significant provider of Women’s health products and services, believes the representation of such a highly qualified woman on the Board would be a valuable contribution to it.

  • Business Wire

    Harbert Discovery Fund Sends Letter to Fellow Enzo Biochem Shareholders

    Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owner of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), sent a detailed letter to shareholders today highlighting HDF’s case for change at Enzo, including the opportunity for shareholders to elect two highly-qualified, fresh voices – Fabian Blank and Peter Clemens – to the Company’s Board of Directors (the "Board") at its 2019 Annual Meeting of Shareholders, which will be held on January 31, 2020.

  • Business Wire

    Enzo Biochem Reports Fiscal First Quarter Results

    Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical needs, today reported results for the fiscal first quarter ended October 31, 2019.

  • Business Wire

    Enzo Biochem Issues Open Letter to Shareholders

    Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical needs, today issued an open letter to shareholders. Full text below:

  • Business Wire

    Enzo Biochem Schedules Teleconference to Discuss First Quarter 2020 Results Tuesday, December 10, 2019 At 4:30 PM E.T.

    Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2020 first quarter results on Tuesday, December 10, 2019, at 4:30 PM E.T.

  • Business Wire

    Enzo Biochem Reports Fiscal Fourth Quarter and Full Year Financial Results

    Company’s Vertically Integrated Life Sciences and Labs Business Generates Breakthrough Diagnostic Testing Approvals and Services in Rapidly Expanding Markets

  • Business Wire

    Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter and Fiscal Year 2019 Results Tuesday, October 15, 2019 at 4:30 PM E.T.

    Enzo Biochem, Inc. (ENZ) will hold a conference call to discuss fiscal 2019 fourth quarter and fiscal year 2019 results on Tuesday, October 15, 2019, at 4:30 PM E.T. To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024.

  • ACCESSWIRE

    Enzo Biochem, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / June 11, 2019 / Enzo Biochem, Inc. (NYSE: ENZ ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on June 11, 2019 at 8:30 AM Eastern ...

  • Business Wire

    Enzo Biochem Reports Fiscal Third Quarter and Nine Months Operating Results

    Company Outlines Three-Pronged Short-Term Value Creation and Growth Strategy

  • Business Wire

    Enzo Biochem Schedules Teleconference to Discuss Third Quarter 2019 Results Tuesday, June 11, 2019 at 8:30 AM E.T.

    To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024. A rebroadcast of the call will be available starting approximately two hours after the conference call ends, through 12 AM (E.T.) Tuesday June 25, 2019.

  • Business Wire

    Enzo Biochem Inc. Announces Issuance of United States Patent for Treatment of Liver Cancer Using Ozanimod

    Enzo Biochem, Inc. (ENZ) today announced that on May 7, 2019 it was issued U.S. Patent No. 10,278,960 entitled “Sphingosine Pathway Modulating Compounds for the Treatment of Cancers” that is directed to methods for treating hepatocellular carcinoma (HCC), the most common human liver cancer, using the compound Ozanimod. Ozanimod is a product of Celgene Corporation (CELG) that is in late-stage clinical development for the treatment of relapsing multiple sclerosis and inflammatory bowel disease. It targets a different part of the same cell signaling pathway, the “sphingosine pathway,” also targeted by Enzo’s proprietary sphingosine kinase inhibitor, SK1-I, which Enzo is currently developing for the treatment of HCC.

  • Business Wire

    Enzo Biochem Reports Second Fiscal Quarter and First Half 2019 Results and Reports Progress on Its Investments and Strategic Goals

    Enzo Biochem, Inc. , an integrated diagnostics and therapeutics company, today reported results for the fiscal quarter and first half ended January 31, 2019 along with providing more detail on its investments in the development of novel diagnostic system and centralized clinical services.

  • Business Wire

    Enzo Biochem Schedules Teleconference to Discuss Second Quarter 2019 Results Tuesday, March 12, 2019 at 8:30 AM E.T.

    To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024. A rebroadcast of the call will be available starting approximately two hours after the conference call ends, through 12 AM (E.T.) Tuesday March 26, 2019.

  • GlobeNewswire

    Factors of Influence in 2019, Key Indicators and Opportunity within The Hain Celestial Group, Allegheny Technologies, NVR, Greif, CorMedix, and Enzo Biochem — New Research Emphasizes Economic Growth

    NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.